Our studies showed that the iRGD conjugated, targeted SCH772984 nanoformulation, combined with free GEM, may be highly effective in killing K-RAS-mutated pancreatic cancer cells due to the controlled and selective drug delivery within the hypoxic and low pH areas of desmoplastic PDAC microenvironment and reduces the production of desmoplastic regulatory proteins in PDAC cells. The gene discussed is KRAS; the disease is pancreatic neoplasm.